Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf



Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company’s two clinical-stage programs during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, highlighting updated interim results from its ongoing non-muscle invasive bladder cancer (NMIBC) s



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *